U.S. Markets closed

Shire plc (SHPG)

NASDAQ Global Select - NASDAQ Global Select Delayed Price. Currency in USD
Add to watchlist
142.84-0.32 (-0.22%)
At close: 4:00PM EDT

143.00 +0.16 (0.11%)
After hours: 4:29PM EDT

People also watch
ALXNJAZZBMRNREGNBAX
Full screen
Previous Close143.16
Open144.44
Bid139.95 x 100
Ask160.00 x 100
Day's Range142.72 - 144.44
52 Week Range139.36 - 209.22
Volume841,301
Avg. Volume1,376,776
Market Cap43.01B
Beta1.65
PE Ratio (TTM)146.50
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.92 (0.66%)
Ex-Dividend Date2017-03-08
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals18 hours ago

    Shire chief financial officer joins Boston ag-tech startup

    Charlestown-based agricultural technology startup Indigo Inc. announced Monday that it is bringing on Jeff Poulton, the chief financial officer of pharmaceutical giant Shire plc, as its own CFO. Poulton will leave Shire at the end of the year, according to the Irish drugmaker. "It has been a privilege to work for Shire and to have played a part in the exceptional growth story of such an inspirational company," Poulton said in a statement.

  • Barrons.com2 days ago

    UPDATE: Shire: There Goes the CFO!

    Update: I spoke with Shire (SHPG) CFO Jeff Poulton about his decision to leave, and he was quick to dispel any concerns that his departure was about anything except his desire to pursue a new opportunity. Poulton also said that calling Shire a specialty-pharmaceutical company is a misnomer, as an overwhelming percentage of revenue now comes from its orphan drug business, a point raised by analyst Evercore ISI analyst Josh Schimmer, who wrote that Shire has "biotech cash flows with a spec pharma valuation" in a note last week. Shares of Shire have fallen 4% to $139.71 at 1:26 p.m. today.

  • Shire Files Marketing Application for Lifitegrast in Europe
    Zacks7 days ago

    Shire Files Marketing Application for Lifitegrast in Europe

    Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.